Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 3Skin Neoplasms 2Neoplasm Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Cyclophosphamide 24Nivolumab 23Ipilimumab 22aldesleukin 19Interleukin-2 15fludarabine 14Specimen Handling 12Dacarbazine 11fludarabine phosphate 10Magnetic Resonance Spectroscopy 10Temozolomide 9Radiosurgery 9Biopsy 9cemiplimab 8Paclitaxel 8dabrafenib 5binimetinib 5Vemurafenib 5Radiotherapy 5Carboplatin 5trametinib 4sargramostim 4encorafenib 4avelumab 4Pemetrexed 4Leucovorin 4Fluorouracil 4Cisplatin 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × peginterferon alfa-2a × Dermatologic × Clear all
NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
8 enrolled 11 charts
Dermatologic

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡